Azacitidine | Aplastic Anemia and MDS International Foundation

Azacitidine

A demethylating agent, this medicine interacts with DNA to restore normal growth of blood cells in the bone marrow.
Brand name: 
5-azacytidine, Vidaza
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)

It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U.S. Food and Drug Administration (FDA) for treating all myelodysplastic syndromes (MDS) subtypes.

Related Clinical Trials

Clinical Trial Status Age Group
A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients Recruiting 18 years and older
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Recruiting 18 years and older
A Phase II Study of 5-Azacitidine and Sargramostim as Maintenance Treatment After Definitive Therapy for Poor-risk AML or MDS Recruiting 6 months to 100 years
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes Recruiting 18 years and older
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) Recruiting 18 years and older
AC220 With 5-Aza or Low Dose Cytarabine Recruiting 18 years and older
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Recruiting 18 years and older
An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia Recruiting 18 years and older
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia Recruiting 18 years or older
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation Not yet recruiting 18 years and older
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR Recruiting
CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies Recruiting 18 years and older
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT) Recruiting 18 years and older
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation Recruiting up to 29 years
Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation Recruiting 18 years and older
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission (QUAZAR AML-001) Recruiting 55 years and older
Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm Recruiting 18 years and older
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Not yet recruiting 18 years and older
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) Recruiting 18 years and older
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse Recruiting 1 year to 75 years
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia Recruiting
Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) Recruiting 18 years and older
Phase 1 Study to Evaluate MEDI4736 in MDS Recruiting 18 years to 99 years
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) Recruiting 18 years and older
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (UPCI 13-165) Recruiting 18 years and older
Randomized Allogeneic Azacitidine Study Recruiting 18 years to 75 years
Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes Recruiting 18 years and older
Selinexor (KPT-330) in Older Patients With Relapsed/Refractory AML (SOPRA) Recruiting 18 years and older
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Recruiting 18 years and older
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation Recruiting 18 years and older
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS Recruiting 18 years and older
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Recruiting 18 years and older
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes Not yet recruiting 18 years and older
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS Recruiting 2 years to 89 years
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes Recruiting 18 years and older

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.